Could ketamine be the answer to treating treatment-resistant major depressive disorder?
General Psychiatry August 1, 2020 Abdullah Ramadan, I. Mansour 16 citations
Major depressive disorder (MDD) is a common, serious, debilitating condition affecting 350 million people worldwide, which remains to be unsatisfactorily treated with 53% of patients still complaining of symptoms after completing their courses with the correct dosage. Ketamine, which was approved by the Food and Drug Administration in 2019, is a potential treatment option for those recalcitrant...